

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:	)	Confirmation No. 6442
	)	
Yardena SAMUELS <i>et al.</i>	)	Group Art No. 1342
	)	
Serial No. 10/591,347	)	Examiner: Goddard, Laura
	)	
Filed: August 31, 2006	)	Atty. Dkt No: 001107.00617
	)	
For: Mutations of the PIK3CA Gene in Human	)	
Cancers	)	

**PETITION TO MAKE SPECIAL**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**RELIEF REQUESTED**

Please advance examination of the subject application pursuant to 37 C.F.R. § 1.102 and M.P.E.P. § 708.02 (X). Please accord “special” status to this application because it relates to cancer.

Please charge the fee under 37 C.F.R. § 1.17(h) of \$130 to our Deposit Account No. 19-0733.

**REASONS WHY RELIEF SHOULD BE GRANTED**

The subject invention contributes to the diagnosis of cancer by providing methods of assessing cancer in humans suspected of having cancer. It also provides methods of treating cancers in humans. These methods are the subjects of claims 1-30 and 31-38, respectively.

The application identifies the PIK3CA gene as a subject of intragenic mutations which are clustered. See paragraph 17. The gene is an excellent marker for detection of early cancer and for monitoring cancer. See paragraph 15. The mutations have been found in a variety of different tumors, making its applicability broad. See paragraph 18.

It is respectfully submitted that petitioners have explained how the invention contributes to the treatment of cancer. Grant of “special” status is therefore appropriate.

Respectfully submitted,

Dated: July 19, 2010

By:           /Sarah A. Kagan/            
Sarah A. Kagan  
Registration No. 32,141

Banner & Witcoff, Ltd.  
Customer No. 22907